【摘要】 目的探讨非霍奇金淋巴瘤(NHL)的临床特征、治疗与预后。方法选取2005年1月至2012年7月收治有完整临床资料的NHL 85例,所有病例按WHO 2001分类标准进行病例分型,并对其临床资料进行分析,总结其与预后的关系。结果 85例患者中男性51例,女性34例,中位年龄52(8～80)岁,中位生存期27.7个月,3年总生存率(OS)44%。IPI分组低危组17例、中低危组15例、中高危组20例、高危组8例,其3年OS率分别为77%、33%、27%、0,差异有统计学意义(P=0.004)。14例使用标准CHOP化疗方案,71例使用强化方案,其3年OS率分别为69%、39%,差异无统计学意义(P=0.368)。单纯化疗组(69例)、放化疗结合组(6例)、移植组(10例)的3年OS率分别为40%、0、78%,差异无统计学意义(P=0.370)。血清LDH升高组与正常组的3年OS率分别为9%、68%,差异有统计学意义(P=0.014)。结论非霍奇金淋巴瘤患者的长期生存与多种因素密切相关,合理检测、调控相关因素可延长患者生存期。不同IPI风险组、血清LDH水平、脾脏浸润可影响患者的预后,强化方案尚未显示明确的治疗优势,尚须探索新的NHL治疗方案。更多还原

【Abstract】 Objective To analyse the prognosis factors of patients with NHL.Methods 85 NHL cases from Jan.2005 to Jul.2012 diagnosed according to WHO criteria were enrolled.We analyzed the relationship between their clinical characteristics and prognosis.Results 51 out of the 85 were male,34 female.The media age was 52 years old;media survival time was 27.7 months;overall survival(OS)at 3 years was 44%.According to IPI score 17 cases were low-risk group,15 in intermediate-low-risk group,20 in intermediate-high-risk group,and 8 in high-risk group.3-year OS of them were 77%,33%,27%,0,respectively(P=0.004).3-year OS in 14 cases treated with CHOP regimen was 69%,and 3-year OS in 71 cases treated with enhanced chemotherapy was 39%(P=0.368).3-year OS in 69 with chemotherapy,6 with chemo-combined radio-therapy,10 with stem cell transplantation were 40%,0,78%,respectively(P=0.370).3-year OS in groups with high level of LDH and normal LDH were 9% and 68%,respectively(P=0.014).Conclusion OS of NHL patients is related to many factors,and new regimens are needed to be explored.更多还原